Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Alliance A021901 - B-LuRE (Bronchial Neuroendocrine Cancer) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called Lutetium Lu 177 dotatate (the study drug) has the potential to shrink or stabilize bronchial neuroendocrine tumors. We will compare how the study drug works to everolimus, which is the usual drug used for this diagnosis.

What is the Condition Being Studied?

Advanced Bronchial Neuroendocrine Cancer

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with a bronchial neuroendocrine tumor
Have never been treated with peptide receptor radionuclide therapy (PRRT)
Have never been treated with mammalian target of rapamycin (mTOR) inhibitors (for example: deforolimus, everolimus, sirolimus, or temsirolimus)

For more information, contact the study team at nick.jeffries@duke.edu.

Grupo etario

Adultos

What is Involved?

Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) a 1 de 2 grupos:

Group1: If you are in this group, you will get the study drug through a vein in the arm every 8 weeks. You will get up to 4 doses of the study drug.
Group2: If you are in this group, you will get the usual drug, everolimus, as a tablet you take by mouth every day.